Torres J L, Pepermans H, Valencia G, Reig F, García-Antón J M, Van Binst G
Laboratory of Peptides, CID-CSIC, Barcelona, Spain.
EMBO J. 1989 Oct;8(10):2925-32. doi: 10.1002/j.1460-2075.1989.tb08442.x.
Two galactosyl derivatives of [DMet2,Pro5] enkephalin-amide (compound 1), namely [DMet2,Pro5] enkephalin [N1.5-beta-D-galactopyranosyl] amide (compound 2) and O1.5-(beta-D-galactopyranosyl) [DMet2,Hyp5] enkephalin-amide (compound 3) have been synthesized. Such glycosylpeptides have been shown to be extremely potent analgesic agonists. The conformational analysis of these three compounds in DMSO-d6 solution has been carried out using two-dimensional NMR methods. Both the parent compound (1) and the beta N-galactosyl derivative (2) show similar NMR parameters which are consistent with fairly rigid beta-strands at both the N-terminus and C-terminus, connected by a glycine residue that displays a mixture between multiple conformational states. Thus, although the beta N-galactosyl derivative (2) has been shown to be significantly more potent than the parent compound (1) in the tail immersion and paw pressure tests of analgesia, no correlation can be established between the conformation of (1) and (2) in DMSO and the difference in analgesic activity. In contrast, important conformational differences with respect to (1) and (2) have been detected in the beta O-galactosyl derivative (3). In this case, only one of the likely conformations for (1) and (2) are consistent with the experimental data. These data show that the position of the galactose residue in compound (3) causes Gly3 to loose flexibility leading to a more rigid folded conformation. Such a change in conformation could be related to the difference in analgesic activity between (2) and (3).
已合成了[DMet2,Pro5]脑啡肽酰胺(化合物1)的两种半乳糖基衍生物,即[DMet2,Pro5]脑啡肽[N1.5-β-D-吡喃半乳糖基]酰胺(化合物2)和O1.5-(β-D-吡喃半乳糖基)[DMet2,Hyp5]脑啡肽酰胺(化合物3)。这类糖基肽已被证明是极其有效的镇痛激动剂。已使用二维核磁共振方法对这三种化合物在DMSO-d6溶液中的构象进行了分析。母体化合物(1)和β-N-半乳糖基衍生物(2)均显示出相似的核磁共振参数,这与N端和C端相当刚性的β链一致,它们由一个在多种构象状态之间呈现混合状态的甘氨酸残基连接。因此,尽管在尾部浸入和爪部压力镇痛试验中,β-N-半乳糖基衍生物(2)已被证明比母体化合物(1)的效力显著更高,但在DMSO中(1)和(2)的构象与镇痛活性差异之间无法建立相关性。相比之下,在β-O-半乳糖基衍生物(3)中检测到了与(1)和(2)相比重要的构象差异。在这种情况下,(1)和(2)可能的构象中只有一种与实验数据一致。这些数据表明,化合物(3)中半乳糖残基位置导致甘氨酸3失去灵活性,从而产生更刚性的折叠构象。这种构象变化可能与(2)和(3)之间镇痛活性的差异有关。